Screening which avoids needle insertion into prostate gland also used to detect skin or breast cancer
AXA PPP healthcare has teamed up with screening service, Check4Cancer, to enhance its prostate cancer diagnosis pathway. Available to its individual, SME and large corporate members, the new approach avoids the invasive routine of taking small samples of tissues for analysis via needle insertion into the prostate gland through the wall of the rectum, which misses cancer 50% of the time and can often lead to infection. Prostate cancer is the most common cancer in men and, according to Prostate Cancer UK, one in eight diagnosed at some point in their lives. The new screening process,...
To continue reading this article...
Join COVER for free
- Unlimited access to real-time news, key trend analysis and industry insights.
- Stay on top of the latest developments around health and wellbeing, diversity and inclusion and the cost of living crisis.
- Receive breaking news stories straight to your inbox in the daily newsletter.
- Members only access to monthly programme 'The COVER Review'
- Be the first to hear about our CPD accredited events and awards programmes.